Teladoc Health (TDOC) Competitors

Teladoc Health has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.

In the previous week, Teladoc Health had 15 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 28 mentions for Teladoc Health and 13 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.33 beat Teladoc Health's score of 0.20 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 76.8% of Teladoc Health shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 0.7% of Teladoc Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Teladoc Health has a net margin of -6.81% compared to CRISPR Therapeutics' net margin of -16,569.77%. Teladoc Health's return on equity of -11.45% beat CRISPR Therapeutics' return on equity.

CRISPR Therapeutics currently has a consensus price target of $64.53, suggesting a potential upside of 23.19%. Teladoc Health has a consensus price target of $7.53, suggesting a potential upside of 12.83%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CRISPR Therapeutics is more favorable than Teladoc Health.

CRISPR Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.

Roku has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Roku, indicating that it is currently the more affordable of the two stocks.

In the previous week, Roku had 44 more articles in the media than Teladoc Health. MarketBeat recorded 72 mentions for Roku and 28 mentions for Teladoc Health. Roku's average media sentiment score of 0.69 beat Teladoc Health's score of 0.20 indicating that Roku is being referred to more favorably in the media.

Roku has a net margin of 4.06% compared to Teladoc Health's net margin of -6.81%. Roku's return on equity of 7.68% beat Teladoc Health's return on equity.

Roku has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Roku currently has a consensus price target of $142.17, suggesting a potential upside of 14.24%. Teladoc Health has a consensus price target of $7.53, suggesting a potential upside of 12.83%. Given Roku's stronger consensus rating and higher possible upside, research analysts clearly believe Roku is more favorable than Teladoc Health.

86.3% of Roku shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 14.0% of Roku shares are held by insiders. Comparatively, 0.7% of Teladoc Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Zoom Communications has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Zoom Communications, indicating that it is currently the more affordable of the two stocks.

In the previous week, Zoom Communications and Zoom Communications both had 28 articles in the media. Zoom Communications' average media sentiment score of 0.96 beat Teladoc Health's score of 0.20 indicating that Zoom Communications is being referred to more favorably in the media.

Zoom Communications has a net margin of 39.03% compared to Teladoc Health's net margin of -6.81%. Zoom Communications' return on equity of 11.88% beat Teladoc Health's return on equity.

Zoom Communications has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Teladoc Health has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Zoom Communications currently has a consensus price target of $95.32, suggesting a potential downside of 12.63%. Teladoc Health has a consensus price target of $7.53, suggesting a potential upside of 12.83%. Given Teladoc Health's higher possible upside, analysts clearly believe Teladoc Health is more favorable than Zoom Communications.

66.5% of Zoom Communications shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 10.8% of Zoom Communications shares are held by insiders. Comparatively, 0.7% of Teladoc Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Teladoc Health has a net margin of -6.81% compared to American Well's net margin of -38.38%. Teladoc Health's return on equity of -11.45% beat American Well's return on equity.

Teladoc Health currently has a consensus price target of $7.53, suggesting a potential upside of 12.83%. American Well has a consensus price target of $7.40, suggesting a potential upside of 16.35%. Given American Well's higher probable upside, analysts plainly believe American Well is more favorable than Teladoc Health.

76.8% of Teladoc Health shares are held by institutional investors. Comparatively, 56.0% of American Well shares are held by institutional investors. 0.7% of Teladoc Health shares are held by insiders. Comparatively, 12.8% of American Well shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

American Well has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.

In the previous week, Teladoc Health had 21 more articles in the media than American Well. MarketBeat recorded 28 mentions for Teladoc Health and 7 mentions for American Well. American Well's average media sentiment score of 0.69 beat Teladoc Health's score of 0.20 indicating that American Well is being referred to more favorably in the news media.

Teladoc Health has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, American Well has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.